Cargando…
The risk of inappropriate empiric treatment and its outcomes based on pathogens in non-ventilated (nvHABP), ventilated (vHABP) hospital-acquired and ventilator-associated (VABP) bacterial pneumonia in the US, 2012–2019
BACKGROUND: Inappropriate empiric antimicrobial treatment (IET) contributes to worsened outcomes. While IET’s differential impact across types of nosocomial pneumonia (NP: non-ventilated [nvHABP], ventilated [vHABP] hospital-acquired and ventilator-associated [VABP] bacterial pneumonia) is establish...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9533487/ https://www.ncbi.nlm.nih.gov/pubmed/36199012 http://dx.doi.org/10.1186/s12879-022-07755-y |
_version_ | 1784802357047984128 |
---|---|
author | Zilberberg, Marya D. Nathanson, Brian H. Puzniak, Laura A. Dillon, Ryan J. Shorr, Andrew F. |
author_facet | Zilberberg, Marya D. Nathanson, Brian H. Puzniak, Laura A. Dillon, Ryan J. Shorr, Andrew F. |
author_sort | Zilberberg, Marya D. |
collection | PubMed |
description | BACKGROUND: Inappropriate empiric antimicrobial treatment (IET) contributes to worsened outcomes. While IET’s differential impact across types of nosocomial pneumonia (NP: non-ventilated [nvHABP], ventilated [vHABP] hospital-acquired and ventilator-associated [VABP] bacterial pneumonia) is established, its potential interaction with the bacterial etiology is less clear. METHODS: We conducted a multicenter retrospective cohort study in the Premier Healthcare Database using an administrative algorithm to identify NP. We paired respective pathogens with empiric treatments. Antimicrobial coverage was appropriate if a drug administered within 2 days of infection onset covered the recovered organism(s). All other treatment was IET. RESULTS: Among 17,819 patients with NP, 26.5% had nvHABP, 25.6% vHABP, and 47.9% VABP. Gram-negative (GN) organisms accounted for > 50% of all infections. GN pathogens were ~ 2 × as likely (7.4% vHABP to 10.7% nvHABP) to engender IET than Gram-positive (GP, 2.9% vHABP to 4.9% nvHABP) pathogens. Although rare (5.6% nvHABP to 8.3% VABP), GN + GP infections had the highest rates of IET (6.7% vHABP to 12.9% nvHABP). Carbapenem-resistant GNs were highly likely to receive IET (33.8% nvHABP to 40.2% VABP). Hospital mortality trended higher in the IET group, reaching statistical significance in GN + GP vHABP (47.8% IET vs. 29.3% non-IET, p = 0.016). 30-day readmission was more common with IET (16.0%) than non-IET (12.6%, p = 0.024) in GN VABP. Generally post-infection onset hospital length of stay and costs were higher with IET than non-IET. CONCLUSIONS: IET is ~ 2 × more common in GN than GP infections. Although the magnitude of its impact varies by NP type, IET contributes to worsened clinical and economic outcomes. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12879-022-07755-y. |
format | Online Article Text |
id | pubmed-9533487 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-95334872022-10-06 The risk of inappropriate empiric treatment and its outcomes based on pathogens in non-ventilated (nvHABP), ventilated (vHABP) hospital-acquired and ventilator-associated (VABP) bacterial pneumonia in the US, 2012–2019 Zilberberg, Marya D. Nathanson, Brian H. Puzniak, Laura A. Dillon, Ryan J. Shorr, Andrew F. BMC Infect Dis Research BACKGROUND: Inappropriate empiric antimicrobial treatment (IET) contributes to worsened outcomes. While IET’s differential impact across types of nosocomial pneumonia (NP: non-ventilated [nvHABP], ventilated [vHABP] hospital-acquired and ventilator-associated [VABP] bacterial pneumonia) is established, its potential interaction with the bacterial etiology is less clear. METHODS: We conducted a multicenter retrospective cohort study in the Premier Healthcare Database using an administrative algorithm to identify NP. We paired respective pathogens with empiric treatments. Antimicrobial coverage was appropriate if a drug administered within 2 days of infection onset covered the recovered organism(s). All other treatment was IET. RESULTS: Among 17,819 patients with NP, 26.5% had nvHABP, 25.6% vHABP, and 47.9% VABP. Gram-negative (GN) organisms accounted for > 50% of all infections. GN pathogens were ~ 2 × as likely (7.4% vHABP to 10.7% nvHABP) to engender IET than Gram-positive (GP, 2.9% vHABP to 4.9% nvHABP) pathogens. Although rare (5.6% nvHABP to 8.3% VABP), GN + GP infections had the highest rates of IET (6.7% vHABP to 12.9% nvHABP). Carbapenem-resistant GNs were highly likely to receive IET (33.8% nvHABP to 40.2% VABP). Hospital mortality trended higher in the IET group, reaching statistical significance in GN + GP vHABP (47.8% IET vs. 29.3% non-IET, p = 0.016). 30-day readmission was more common with IET (16.0%) than non-IET (12.6%, p = 0.024) in GN VABP. Generally post-infection onset hospital length of stay and costs were higher with IET than non-IET. CONCLUSIONS: IET is ~ 2 × more common in GN than GP infections. Although the magnitude of its impact varies by NP type, IET contributes to worsened clinical and economic outcomes. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12879-022-07755-y. BioMed Central 2022-10-05 /pmc/articles/PMC9533487/ /pubmed/36199012 http://dx.doi.org/10.1186/s12879-022-07755-y Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Zilberberg, Marya D. Nathanson, Brian H. Puzniak, Laura A. Dillon, Ryan J. Shorr, Andrew F. The risk of inappropriate empiric treatment and its outcomes based on pathogens in non-ventilated (nvHABP), ventilated (vHABP) hospital-acquired and ventilator-associated (VABP) bacterial pneumonia in the US, 2012–2019 |
title | The risk of inappropriate empiric treatment and its outcomes based on pathogens in non-ventilated (nvHABP), ventilated (vHABP) hospital-acquired and ventilator-associated (VABP) bacterial pneumonia in the US, 2012–2019 |
title_full | The risk of inappropriate empiric treatment and its outcomes based on pathogens in non-ventilated (nvHABP), ventilated (vHABP) hospital-acquired and ventilator-associated (VABP) bacterial pneumonia in the US, 2012–2019 |
title_fullStr | The risk of inappropriate empiric treatment and its outcomes based on pathogens in non-ventilated (nvHABP), ventilated (vHABP) hospital-acquired and ventilator-associated (VABP) bacterial pneumonia in the US, 2012–2019 |
title_full_unstemmed | The risk of inappropriate empiric treatment and its outcomes based on pathogens in non-ventilated (nvHABP), ventilated (vHABP) hospital-acquired and ventilator-associated (VABP) bacterial pneumonia in the US, 2012–2019 |
title_short | The risk of inappropriate empiric treatment and its outcomes based on pathogens in non-ventilated (nvHABP), ventilated (vHABP) hospital-acquired and ventilator-associated (VABP) bacterial pneumonia in the US, 2012–2019 |
title_sort | risk of inappropriate empiric treatment and its outcomes based on pathogens in non-ventilated (nvhabp), ventilated (vhabp) hospital-acquired and ventilator-associated (vabp) bacterial pneumonia in the us, 2012–2019 |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9533487/ https://www.ncbi.nlm.nih.gov/pubmed/36199012 http://dx.doi.org/10.1186/s12879-022-07755-y |
work_keys_str_mv | AT zilberbergmaryad theriskofinappropriateempirictreatmentanditsoutcomesbasedonpathogensinnonventilatednvhabpventilatedvhabphospitalacquiredandventilatorassociatedvabpbacterialpneumoniaintheus20122019 AT nathansonbrianh theriskofinappropriateempirictreatmentanditsoutcomesbasedonpathogensinnonventilatednvhabpventilatedvhabphospitalacquiredandventilatorassociatedvabpbacterialpneumoniaintheus20122019 AT puzniaklauraa theriskofinappropriateempirictreatmentanditsoutcomesbasedonpathogensinnonventilatednvhabpventilatedvhabphospitalacquiredandventilatorassociatedvabpbacterialpneumoniaintheus20122019 AT dillonryanj theriskofinappropriateempirictreatmentanditsoutcomesbasedonpathogensinnonventilatednvhabpventilatedvhabphospitalacquiredandventilatorassociatedvabpbacterialpneumoniaintheus20122019 AT shorrandrewf theriskofinappropriateempirictreatmentanditsoutcomesbasedonpathogensinnonventilatednvhabpventilatedvhabphospitalacquiredandventilatorassociatedvabpbacterialpneumoniaintheus20122019 AT zilberbergmaryad riskofinappropriateempirictreatmentanditsoutcomesbasedonpathogensinnonventilatednvhabpventilatedvhabphospitalacquiredandventilatorassociatedvabpbacterialpneumoniaintheus20122019 AT nathansonbrianh riskofinappropriateempirictreatmentanditsoutcomesbasedonpathogensinnonventilatednvhabpventilatedvhabphospitalacquiredandventilatorassociatedvabpbacterialpneumoniaintheus20122019 AT puzniaklauraa riskofinappropriateempirictreatmentanditsoutcomesbasedonpathogensinnonventilatednvhabpventilatedvhabphospitalacquiredandventilatorassociatedvabpbacterialpneumoniaintheus20122019 AT dillonryanj riskofinappropriateempirictreatmentanditsoutcomesbasedonpathogensinnonventilatednvhabpventilatedvhabphospitalacquiredandventilatorassociatedvabpbacterialpneumoniaintheus20122019 AT shorrandrewf riskofinappropriateempirictreatmentanditsoutcomesbasedonpathogensinnonventilatednvhabpventilatedvhabphospitalacquiredandventilatorassociatedvabpbacterialpneumoniaintheus20122019 |